Yescarta denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for yescarta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Yescarta: Medical Necessity

UHC requires prior authorization for Yescarta (axicabtagene ciloleucel) and applies detailed medical necessity criteria drawn from its clinical coverage policy. A medical necessity denial means UHC's reviewers concluded that the submitted documentation did not satisfy one or more of their stated criteria — such as confirmation of the specific diagnosis and disease classification, documentation of the required number and types of prior lines of therapy, adequate performance status assessment, or confirmation that the patient is being treated at a qualified treatment center.

## Why This Is Appealable

Medical necessity denials for Yescarta are frequently overturned at appeal when the clinical record is complete and directly mapped to UHC's stated criteria. The denial letter must by law tell you which specific criteria were not met — that explanation is the foundation of your appeal. A targeted response that addresses each unmet criterion with specific chart documentation is far more effective than a general letter of support.

## Federal Appeal Framework

• Internal appeal: File under ACA §2719 / ERISA §503 within the deadline on your denial notice. Expedited internal appeal (72-hour turnaround) is available and strongly recommended for active oncology cases.
• External review: If the internal appeal fails, an Independent Review Organization reviews UHC's determination independently. The external review window is up to four months from final internal denial. Expedited external review is available given the life-threatening nature of the underlying condition.
• Concurrent peer-to-peer: Before or during the internal appeal, request a peer-to-peer review between your oncologist and UHC's medical director. This call frequently resolves medical necessity disputes without a formal appeal.

## Documentation to Collect

1. Diagnosis confirmation — pathology report(s) confirming the specific histologic type and any required classification features; staging imaging; flow cytometry or molecular testing as applicable. 2. Prior-treatment history — a chronological list of every prior regimen with start/end dates, response assessment (per standard oncology criteria), and reason for discontinuation. The number and type of prior lines must satisfy the FDA label requirements — verify against the current label. 3. Performance status assessment — documented ECOG or Karnofsky score from a recent clinic visit. 4. Treatment center qualification — documentation that the administering center is a certified CAR-T treatment facility, as UHC requires. 5. Prescriber medical necessity letter — your oncologist should address each UHC criterion point-by-point, citing specific chart dates, reports, and findings. The letter should reference the applicable oncology guideline organization's support for Yescarta in your clinical setting.

## Criteria-Mapping Structure

Obtain UHC's current Yescarta / CAR-T medical policy. List every criterion verbatim. For each criterion, cite the specific document, date, and finding from your chart that satisfies it. Submit this as a structured exhibit alongside the medical necessity letter.